Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial. - Martín M; Rodriguez-Lescure A; Reboredo C; Chen E; Ruiz-Borrego M; Santaballa Bertran A; Rodríguez CA; Martinez Jañez N; Alba E; Tran K; Pelaez Fernandez I; Álvarez I; et al. (Clinical Cancer Research, 2026)